188 Re-MAG 3 -filled balloon) using intravascular ultrasound (IVUS) in patients with in-stent restenosis (ISR). Long-term effects of ␤-irradiation on intimal hyperplasia (IH) within the stented segment and vessel and lumen dimensions of nonstented adjacent segments in patients with ISR have not been sufficiently evaluated. Two-year follow-up IVUS was performed in 30 patients with patent ISR segments at 6-month follow-up angiography. Serial IVUS images were acquired at five equidistant intrastent sites and at three different reference segment sites. IH burden (%) was defined as 100 ؋ (IH/stent area). Mean intrastent IH area and IH burden significantly increased between 6 and 24 months, from 2.1 ؎ 1.1 to 2.6 ؎ 1.4 mm 2 (P < 0.001) and from 26% ؎ 10% to 33% ؎ 14% (P < 0.001), respectively. There was a significant decrease of mean external elastic membrane (from 10.1 ؎ 3.9 to 9.7 ؎ 3.9 mm 2 ; P ‫؍‬ 0.015) and lumen area (from 5.6 ؎ 2.3 to 5.1 ؎ 2.3 mm 2 ; P ‫؍‬ 0.021) within distal reference segments between 6 and 24 months. Target lesion revascularization (TLR) was performed in six patients (20%) between 6 and 24 months after ␤-irradiation therapy. There were no significant differences between TLR and non-TLR groups except for a smaller minimum lumen area at 24 months in the TLR group. Because of a small amount of late loss between 6 and 24 months, most irradiated ISR vessel segments remained stable for up to 2 years. However, quantitative evidence of late catch-up was evident in most patients and was significantly associated with 24-month TLR in some patients.
INTRODUCTION
Studies of intracoronary brachytherapy in patients with in-stent restenosis (ISR) demonstrated a reduction of 6-month angiographic restenosis and 9-month target lesion revascularization (TLR) compared with control groups [1] [2] [3] [4] [5] [6] . This was supported by 6-month follow-up intravascular ultrasound (IVUS) studies that also showed a significant inhibition of intimal hyperplasia (IH), the cause of first-time and recurrent ISR [7] [8] [9] . Our reports of ␤-irradiation ISR treatment with 188 Re-MAG 3 -filled balloon showed similar results [3, 9] . Recently, clinical and angiographic studies have demonstrated long-term (Ն 2-year) effectiveness of brachytherapy [10 -12] . Late thrombosis and restenosis, which occurred beyond 6 months after intracoronary brachytherapy, were also reported [1, 4, 13, 14] . However, there is little long-term IVUS data beyond 6 months on the effectiveness of brachytherapy in ISR. One report of patients with non-ISR lesions treated with a radioactive stent showed suppression of IH at 6 months, but late catch-up at 12 months [15] . Therefore, the objective of the current study was to use serial (postirradiation and 6-and 24-month follow-up) IVUS to evaluate the long-term (24-month) effectiveness after ␤-radiation therapy using 188 Re-MAG 3 -filled balloon in patients with diffuse ISR.
MATERIALS AND METHODS

Study Population
␤-irradiation therapy with a 188 Re-MAG 3 -filled balloon was performed for patients with diffuse ISR (lesion length Ͼ 10 mm, diameter stenosis Ͼ 50%) [3] . Inclusion criteria were diffuse ISR in a native coronary artery with angina, demonstrable objective myocardial ischemia, and written informed consent. Exclusion criteria were acute myocardial infarction within 72 hr, poor renal function, pregnancy, contraindication to antiplatelet therapy, and concomitant serious disease with an expected survival of Ͻ 2 years. Our institutional review board approved this study. The angiographic follow-up was requested at 6 months in all patients who underwent intracoronary radiation therapy. Seventy-five patients were enrolled in this study; 73 patients underwent 6-month angiography. Among patients with 6-month angiograms, 2-year follow-up study was performed in 34 selected patients. Among patients with 6-month angiograms, 2-year angiographic follow-up study was performed in 34 selected patients who showed patent irradiation segments at 6 months, did not require TLR at 6 months, and gave their written informed consent to participate in a 2-year follow-up study at the time of the 6-month follow-up. Any major adverse cardiac events and typical chest pain did not occur in these selected patients between 6-and 24-month follow-up. Among these 34 patients, late total occlusion of a distal part of the irradiated segment occurred in two patients (5.9%) at 2-year follow-up. Because IVUS catheter did not pass through the totally occluded lesion, 2-year follow-up IVUS images were not acquired. Both late total occlusion patients were asymptomatic and had a negative exercise test; both were treated medically. Two additional patients were excluded from IVUS analysis because of poor image quality in one patient and a mismatching of IVUS images between 6-and 24-month studies in one patient. The irradiated segment in these two patients was patent at 2-year follow-up. Therefore, 30 patients were included in this 2-year IVUS analysis.
Radiation Delivery System, Dosimetry, and Procedure
The methods of brachytherapy were described in detail in a previous report [3] . The delivery system was a 188 Re-MAG 3 -filled angioplasty balloon. Liquid 188 Re is a high-energy ␤-emitter that is available daily from a 188 W/ 188 Re generator (Oak Ridge National Laboratory, Oak Ridge, TN). From the dosimetry data, the irradiation time was calculated to deliver 15 Gy at 1.0 mm deep into the vessel wall from the balloon/artery interface [3] . To avoid geographic miss, irradiation was performed to cover the proximal and distal nonstented injured segments as well as the proximal and distal uninjured margins by Ͼ 5 mm.
All the patients were pretreated with aspirin 200 mg/ day, ticlopidine 500 mg/day, and cilostazol 200 mg/day for 2 days. Ticlopidine was given for 1 month, but aspirin and cilostazol were administered for more than 6 months after irradiation [3] .
IVUS Imaging Protocol
Postirradiation and 6-and 24-month follow-up IVUS studies were performed in identical fashion. Intracoronary 0.2 mg nitroglycerin was administered. The ultrasound catheter was advanced approximately 10 mm beyond the lesion site, and an imaging run was performed from beyond the lesion site to the aorto-ostial junction. The studies were performed with a commercially available system (Boston Scientific/Cardiovascular Imaging System, San Jose, CA); this system used a 30 MHz single-element beveled transducer mounted on the end of a flexible shaft and rotated at 1,800 rpm within a 3.2 Fr short-monorail imaging sheath. With this system, the transducer was withdrawn automatically at 0.5 mm/sec to perform the imaging sequence. Ultrasound studies were recorded on a 0.5Љ high-resolution s-VHS tape for offline analysis. The postirradiation IVUS imaging run was the final step in the intervention procedure. At 6-and 24-month follow-up, IVUS imaging was performed before any subsequent intervention.
Quantitative Coronary Angiographic (QCA) Analysis
Coronary angiography was performed after the administration of 0.2 mg intracoronary nitroglycerin. Using the guiding catheter for magnification calibration and an online QCA system (Ancor V2.0, Siemens, Germany), the minimal luminal diameter (MLD) was measured. QCA measurements of the MLD within 5 mm beyond irradiated segments were performed before and after intervention and at 6-and 24-month follow-up from diastolic frames in a single matched view showing the smallest luminal diameter. Reference diameter was selected from user-defined segments proximal and distal to the lesion. Lesion length was determined by the shoulder-to-shoulder extent of narrowing in the view with the least amount of foreshortening.
Quantitative IVUS Measurements
Measurements were performed according the American College of Cardiology clinical expert consensus document on standards for acquisition, measurement, and reporting of IVUS studies [16] by the investigator who was blinded to clinical and angiographic data. Measurements included external elastic membrane (EEM), stent, lumen, plaque and media (P&M ϭ EEM Ϫ lumen), and IH (stent Ϫ lumen) cross-sectional areas (CSA). IH burden (%) was defined as 100 ϫ (IH/stent CSA).
On playback of the postirradiation and 6-and 24-month follow-up IVUS studies, matching image slices were acquired at three different sites of the nonstented adjacent segment at 1, 2, and 4 mm from the stent margin and at five equidistant sites within the stented segment ( Fig. 1) . Mean proximal reference, intrastent, and distal reference values are reported. In practice, the 6-month follow-up target slices were first analyzed; then the distance from each target slice to the closest identifiable axial landmark (i.e., stent edge) was measured (using seconds or frames of videotape). Finally, this distance was used to identify the corresponding slices on the postirradiation and 24-month IVUS studies. Vascular and perivascular markings were also used to confirm image slice identification. When necessary, the analysis was done side by side and the imaging runs were studied frame by frame to ensure that matching image slices were measured. The minimum lumen CSA was also determined.
Statistical Analysis
Categorical data are presented as frequencies. Continuous data are presented as mean Ϯ SD. Comparison was performed with paired and nonpaired Student's t-test, Fisher's exact test, and ANOVA with repeated measures using the Bonferroni correction for post hoc analyses. P value Ͻ 0.05 was considered statistically significant.
RESULTS
The initial and long-term angiographic follow-up was performed at a mean of 6.1 Ϯ 1.2 and 24.0 Ϯ 2.8 months after the index procedure, respectively. Angiographically, restenosis (diameter stenosis Ͼ 50%) occurred in eight patients between 6 and 24 months after ␤-irradiation therapy. The location of the restenosis was the edge of irradiation in two patients and within the irradiated segment in six patients. Six out of these eight restenosis patients (20%) underwent TLR; TLR was not performed in the remaining two patients because of the intermediate degree of stenosis and absence of symptoms. Baseline clinical characteristics and QCA measurements between patients with and without TLR are shown in Tables I  and II , respectively. MLD progressively decreased from 2.7 Ϯ 0.5 mm at postintervention to 2.3 Ϯ 0.7 mm at 6-month follow-up to 1.7 Ϯ 0.7 mm at 2-year follow-up (ANOVA P Ͻ 0.001); the MLD at 24 months was significantly smaller than that at 6 months (P ϭ 0.003).
IVUS Results
Serial IVUS findings are presented in Table III . In the stented segment, there was no change in stent CSA. There was a trend for an increase in IH CSA at 6 months (P ϭ 0.14 vs. postirradiation) and a significant increase at 24 months (P Ͻ 0.001 vs. 6 months follow-up). This resulted in a trend for a decrease in lumen CSA at 6 months (P ϭ 0.11) and a significant decrease in lumen CSA at 24 months (P Ͻ 0.001 vs. 6-month follow-up). The IH burden (IH/stent CSA) measured 23% Ϯ 8% postirradiation, 26% Ϯ 10% at 6 months (P ϭ 0.10 vs. postirradiation), and 33% Ϯ 14% at 24-month follow-up (P Ͻ 0.001 vs. 6-month follow-up).
In the distal nonstented segment, there was an increase in EEM CSA at 6 months and a decrease in EEM CSA at 24 months (both P Ͻ 0.05). The decrease in EEM CSA at 24 months was accompanied by a decrease in lumen CSA (P Ͻ 0.05 vs. 6-month follow-up). In the proximal nonstented segment, there was no change in EEM or lumen CSA at 6 months, but a trend for a decrease in EEM CSA and lumen CSA from 6 to 24 months (P ϭ 0.17 and P ϭ 0.19, respectively). There were no significant changes in P&M CSA between 6 and 24 months in either the proximal or the distal nonstented adjacent segments.
IVUS findings between patients with and without TLR are shown in Table IV . There was no significant difference of IVUS measurement from irradiation to 6-month follow-up between the two groups except for a smaller minimum lumen CSA at 24 months in the TLR group. Figure 2 showed the ⌬IH CSA between postirradiation and 6 months and that between postirradiation and 24 months.
DISCUSSION
The current study demonstrated late catch-up occurred in both stented and nonstented adjacent segments in asymptomatic patients between 6 and 24 months after intracoronary brachytherapy. The main mechanism of late lumen loss between 6 and 24 months was IH proliferation within the stented segment and vessel shrinkage rather than plaque proliferation in the nonstented adjacent segment. The irradiated ISR vessel segment remained stable for up to 2 years in most patients. However, significant late catch-up was associated with late TLR in some patients between 6 and 24 months after irradiation. In conventional stenting of de novo lesions, restenosis or renarrowing of MLD usually occurred within 6 months after stenting. In patients who were restenosisfree at 6 months after de novo stenting, late catch-up rarely occurred after 6 months [17] . However, in radioactive stent implantation into de novo lesions, late progression of IH was observed from 6 months to 1 year in a 1-year IVUS follow-up study. This suggests that with brachytherapy, IH proliferation is delayed rather than prevented [15] .
In ISR lesions treated with intracoronary brachytherapy, several studies showed late catch-up: occurrence of TLR and decrease in QCA MLD between 6 and 24 months [10, 12] . However, there are no published data to evaluate long-term (Ն 2-year) changes of IH using serial IVUS in ISR lesions. The current IVUS study in the ISR lesions treated with intracoronary brachytherapy showed late catch-up in most patients as well as TLR in six patients (20%), a progressive decrease in QCA MLD and IVUS minimum lumen CSA.
Our previous IVUS studies showed that ␤-irradiation therapy inhibits IH proliferation within the stented segment and promotes positive remodeling in nonstented adjacent segments at 6-month follow-up [9, 18] . The cur- [18] and late vessel shrinkage at 2 years. This biphasic remodeling response was more prominent in the distal compared to the proximal reference segment; this may be partly related to dosing since the distal segment is smaller than the proximal segment. A biphasic remodeling response has been reported in other nonstented interventional environments [19] . Several clinical and angiographic studies demonstrated long-term (Ն 2-year) safety and efficacy of intracoronary brachytherapy [10, 12] . The current study also showed long-term safety and efficacy in most patients. Overall, the amount of late loss between 6 and 24 months was small; mean IH burden in the stented segment rose from 26% Ϯ 10% to 33% Ϯ 14%, and mean lumen CSA in the proximal and distal nonstented adjacent segment decreased from 8.0 Ϯ 3.0 to 7.5 Ϯ 3.2 mm 2 and from 5.6 Ϯ 2.3 to 5.0 Ϯ 2.3 mm 2 , respectively. However, in patients with late TLR and restenosis, serial IVUS studies showed more IH proliferation and a greater lumen loss at 24 months. Previous study suggested that a larger radiation dose is associated with a longer delay in the restenosis process [20] . The radiation dose in the current study was 15 Gy at 1.0 mm deep into the vessel wall. Longer-term (Ͼ 2-year) follow-up IVUS study may be needed to evaluate the exact timing of plateau phase or cessation of this late catch-up phenomenon. In addition, one previous study has shown that radiation failure is associated with a heterogeneous increase in IH manifested quantitatively as a greater decrease in minimum lumen area than an increase in IH volume or mean IH area [21] .
Late stent thrombosis is a new phenomenon occurring as a complication of vascular brachytherapy. Among the early trials, the rate of late thrombosis was reported to be 5.3-9.2% [1, 4, 13, 14] . Predictors of late thrombosis are placement of a new stent and in-stent restenosis lesion length [14] . Previous study reported that 6 months of clopidogrel reduces the rate of late thrombosis after ␥-irradiation to 2.5% compared with only 1 month of clopidogrel for patients with ISR treated with ␥-radiation [22] . Recent study showed that 12 months of clopidogrel is superior to 6 months in reducing overall major cardiac events and TLR [23] . All 34 patients in this study received ticlopidine for 1 month and both aspirin and cilostazol during the 2-year follow-up period [3] . No reimbursement of clopidogrel in insurance system of our country resulted in the use of cilostazol instead of clopidogrel. No late thrombosis, which was associated with major adverse cardiac events and typical chest pain, occurred during the 2-year follow-up period. Two patients with late total occlusion of the distal segment who were excluded from this IVUS analysis were asymptomatic. Therefore, these two patients might have had an exaggerated manifestation of the late catch-up phenomenon.
Study Limitations
This study has several limitations. First, the number of patient was relatively small and perhaps insufficient to determine any predictors of radiation failure between 6 and 24 months. Second, 2-year follow-up IVUS was performed in only a selected group of patients. However, the current study demonstrated the quantitative evidence of late catch-up between 6 and 24 months after intracoronary brachytherapy even in asymptomatic patients. Third, this study was performed with ␤-radiation therapy with a 188 Re-MAG 3 -filled balloon and a radiation dosage of 15 Gy. Thus, the results of the present study cannot be compared to those of the other studies using different radiation sources, radiation dosage, and delivery methods. Fourth, there were no control patients.
Because of a small amount of late loss between 6 and 24 months, most irradiated ISR vessel segments remained stable for up to 2 years. However, quantitative evidence of late catch-up was present in most patients and was significantly associated with 24-month TLR in some patients.
